Combining a complement inhibitor with rituximab rapidly controls severe autoimmune hemolytic anemia (AIHA), including cold agglutinin syndrome, according to a case series published in the Annals of Hematology by researchers at the University of Freiburg Medical Center in Germany. The findings describe an innovative therapeutic approach that achieved stable remission in three patients, with two able to discontinue the complement inhibitor safely without recurrence.
Rapid Remission in Severe AIHA Cases
AIHA occurs when antibodies target red blood cells, destroying them through hemolysis, a process heavily driven by the complement system in cold-reactive cases. To combat this, researchers at the University of Freiburg Medical Center administered a combination of rituximab—which depletes B-cells responsible for producing self-reactive antibodies—and complement inhibition. Because Enjaymo (sutimlimab) was not immediately available upon admission, the patients initially received a single dose of eculizumab (marketed as Soliris) as bridging therapy before switching to a weight-based regimen of Enjaymo. According to the study, all three patients also received azithromycin to prevent bacterial infections due to the combined suppression of immune defenses.
Did you know? Enjaymo is specifically approved to reduce red blood cell destruction in adults with cold agglutinin disease by targeting the C1s complement protein, but it typically requires ongoing, indefinite maintenance dosing unless combined with B-cell depletion strategies.
Case Breakdown: Patient Outcomes and Treatment Discontinuation
The first patient, a 54-year-old woman admitted with severe anemia and cold agglutinins, failed to respond to corticosteroids. After receiving blood transfusions alongside eculizumab, rituximab, and Enjaymo, her hemoglobin levels gradually improved. Although she experienced a subsequent hospitalization for severe neutropenia and an infection that resolved with antibiotics and G-CSF, her hemolysis markers normalized. Enjaymo was stopped after six doses due to joint pain and low white blood cell counts, yet her hemoglobin remained normal six months post-diagnosis without ongoing treatment, according to the researchers.
The second patient, a 58-year-old woman with a history of immune thrombocytopenia and a hemoglobin level that dropped to 4.9 g/dL, presented with features of both warm- and cold-reactive antibodies. Classified by the authors as warm AIHA with possible complement activation, she received steroids, a blood transfusion, eculizumab, rituximab, and Enjaymo. At her own request, she stopped Enjaymo after six doses.
The third patient, a 23-year-old man with secondary cold agglutinin syndrome triggered by a respiratory infection, presented with critically low blood pressure and required vasopressors and plasmapheresis. Following stabilization with red blood cell transfusions, corticosteroids, eculizumab, and rituximab, he continued maintenance therapy with Enjaymo. While he experienced a brief readmission for abdominal pain and abnormal liver tests that resolved spontaneously, his hemoglobin remained stable and he no longer required transfusions three weeks post-admission.
The study authors noted that this dual-action strategy successfully interrupted the cycle of antigen exposure and autoantibody production. By rapidly suppressing complement-mediated hemolysis while clearing autoreactive B-cells, the combination offers a promising therapeutic pathway. However, the researchers emphasized that the efficacy and safety of combining Enjaymo and rituximab must be evaluated in larger, controlled clinical trials before it becomes a standard protocol.
Pro Tip: Clinicians evaluating combination therapies for complex hematologic disorders should closely monitor patients for secondary neutropenia and infection risks arising from multi-modal immune suppression.
Frequently Asked Questions
What is autoimmune hemolytic anemia (AIHA)?
AIHA is a rare blood disorder where the immune system mistakenly produces antibodies that attack and destroy the body’s own red blood cells, leading to severe anemia and fatigue.
How does Enjaymo work in cold agglutinin disease?
Enjaymo (sutimlimab) is a monoclonal antibody that targets the C1s complement protein, blocking the classical complement pathway and stopping red blood cell destruction.
Can complement inhibitors be stopped permanently?
In this recent case series, two out of three patients successfully discontinued Enjaymo without disease recurrence during the follow-up period, though researchers stress that further clinical trials are needed to confirm long-term safety and efficacy.
Want to stay informed on the latest breakthroughs in hematology research? Subscribe to our newsletter or explore our related articles on rare blood disorders today.